FindTrial
Sign In

Resistant bacteria in Neonatal infections

Clinical profile and genotypic spectrum of carbapenem resistant Enterobacteriaceae in neonatal sepsis: A Prospective observational Study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/05/109890
Enrollment
73
Registered
2026-05-04
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: P368- Other bacterial sepsis of newborn

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil

Sponsors

INDIRA GANDHI INSTITUTE OF CHILD HEALTH
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: NEONATES OF AGE 28 DAYS/ 44 WEEKS PMA

Exclusion criteria

Exclusion criteria: 1.Neonates with polymicrobial or contaminated isolates. 2. Repeat isolates from the same patient. 3. Neonates with major congenital malformations.

Design outcomes

Primary

MeasureTime frame
To describe the clinical profile of neonates with Carbapenam Resistant Enterobacteriaceae (CRE).Timepoint: 4 weeks—

Secondary

MeasureTime frame
To describe the genotypic spectrum of CRE isolates in neonates To determine the proportion of CRE harboring carbapenamase genes in isolates that are phenotypically susceptible to carbapenems in blood culture. To describe the clinical characteristics & risk factors among the neonates infected with Carbapenamse producing Carbapenem-resistant Enterobacteriaceae (CRE) and non carbapenamase producing CRE (non-CP CRE).Timepoint: 4weeks—

Countries

India

Contacts

Public ContactDR SIVANESAN KANDASAMY

INDIRA GANDHI INSTITUTE OF CHILD HEALTH, BANGALORE

prathikbh@gmail.com9717235721

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 11, 2026